With the timing right and new capital in its hands, CerviLenz is forging ahead with the commercialization of its device to aid in the prevention of preterm birth. The Cleveland-area company has raised at least $2 million, as disclosed in U.S. Securities and Exchange Commission documents, and hired new sales representatives to help drive adoption […]
Women’s health medical device company CerviLenz has raised an additional $2 million in equity, according to a recently filed regulatory document. The funding would seem to bring the Cleveland-area device maker’s series A round of investment to $10.35 million. Company officials in October pegged the series A at $8.35 million, but declined comment on the […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The U.S. Food and Drug Administration is soon expected to decide whether to approve a progesterone vaginal gel that could reduce preterm birth in women. Cleveland-area CerviLenz, which makes a device to measure the length of a woman’s cervix, is closely watching the FDA’s decision. Approval of the drug, Prochieve 8%, could speed adoption of […]
This post is sponsored by Cervilenz Inc. 12.9 million babies are born too soon every year around the world, and 1 million of those babies die. The United States has the second-highest rate of prematurity in the world. Here, 1 of 8 babies is born prematurely, and these early deliveries are the leading cause of […]
This post is sponsored by Cervilenz Inc. November is a time for thanks. Every day, I am thankful for my husband, Jim, and our three healthy children — Emmett, Riley, and Allie. But, this time of year is a mixed blessing for me. November is Prematurity Awareness Month. Every minute of every day, a baby is […]
Women’s health medical device company Cervilenz has increased its series A round of investment to $8.35 million, thanks to a recent tranche of funding from existing investors. Cleveland-area Cervilenz plans to use the funding to continue commercialization of its device, which provides a means of accurately and inexpensively measuring a pregnant woman’s cervix. A short […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
MedCity News’ Brandon Glenn discusses the opportunities a new progesterone drug could have for Ohio medical device company CerviLenz on this week’s edition of Health Journal on ONN. CerviLenz’s device provides a means of accurately and inexpensively measuring a pregnant woman’s cervix. The new drug, Prochieve 8%, is a gel that was associated in a […]
Pending regulatory approval of a progesterone drug could open up a new, lucrative market in helping prevent premature births for medical device maker CerviLenz. The drug, Prochieve 8%, is a gel that was associated in a Phase 3 clinical trial with a 45 percent reduction in preterm births in pregnant women with a short cervix, […]
Medical device startup CerviLenz Inc. has appointed its first chief financial/operating officer: Federica “Freddi” O’Brien, a certified public accountant who spent the last decade working with bioscience companies. “I have 30 years of experience working with middle-market, development-stage companies, as well as big pharma companies,” O’Brien said. “I had been tracking CerviLenz since I heard […]
MedCity News President Chris Seper appeared on air of content partner WKYC-TV, discussing three Cleveland-area medical device companies: AxioMed Spine, CerviLenz and Neuros Medical.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
CerviLenz is a simple, low-tech medical device that prompts a “why didn’t I think of that?” response from many obstetricians. Yet the device that quickly, accurately and inexpensively measures a pregnant woman’s cervix could help answer the $26 billion-a-year problem of preterm births in the United States. And CerviLenz, the Chagrin Falls, Ohio, company commercializing […]
Obstetricians, nurse-midwives and labor and delivery nurses now have a powerful — and inexpensive — tool for assessing a woman’s risk of delivering a baby too early. CerviLenz. The disposable device made by CerviLenz Inc. — a Chagrin Falls, Ohio, startup — was introduced today at the American Academy of Obstetricians and Gynecologists annual meeting […]
The company is developing a disposable device that measures the length of a woman's cervix to help predict risks of preterm birth. It is potentially easier, less costly and just as accurate as the transvaginal ultrasound device used in only high-risk pregnancies. It could be in the market by 2010.